No Data
No Data
No Data
No Data
No Data
Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says
Sarepta Therapeutics' (SRPT) regulatory review of its Elevidys therapy for Duchenne muscular dystrophy is advancing faster than anticipated, Morgan Stanley said in a report emailed Thursday. "Overall,
MT Newswires15:42 ET
Wingstop's Higher Same-Store Sales 2024 Guide Implies Slowing From Q1, Though More Upside Seen, Morgan Stanley Says
Wingstop's (WING) higher same-store sales guidance for 2024 implies sequential slowing from Q1, though new customers may trigger more upside, Morgan Stanley said in a report emailed Thursday. Morgan S
MT Newswires15:06 ET
Garmin Outperforming Peers Despite Offering Products at a Premium, Morgan Stanley Says
Garmin's (GRMN) Q1 results reflect the company's likeliness to grow its revenue and earnings by double digits next year, Morgan Stanley said in a note emailed Thursday. Calling the company's Q1 an "al
MT Newswires15:04 ET
Q2 Holdings Coverage Assumed by Morgan Stanley at Equal-Weight
Q2 Holdings Coverage Assumed by Morgan Stanley at Equal-Weight
Dow Jones13:28 ET
Morgan Stanley Assumes Q2 Holdings at Equal-Weight, Raises Price Target to $50
Morgan Stanley analyst James Faucette assumes Q2 Holdings (NYSE:QTWO) with a Equal-Weight rating and raises Price Target to $50.
Benzinga13:17 ET
Morgan Stanley Adjusts Price Target on Marriott International to $256 From $263
Marriott International (MAR) has an average hold rating and a price target range of $200 to $278, according to analysts polled by Capital IQ. Price: 234.21, Change: +0.35, Percent Change: +0.15
MT NewswiresMay 2 10:01 ET
No Data
No Data